ERAS-601 + Cetuximab + Pembrolizumab
Phase 1Active 0 watching 0 views this week💤 Quiet
30
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Advanced or Metastatic Solid Tumors
Conditions
Advanced or Metastatic Solid Tumors
Trial Timeline
Dec 15, 2020 → Feb 1, 2026
NCT ID
NCT04670679About ERAS-601 + Cetuximab + Pembrolizumab
ERAS-601 + Cetuximab + Pembrolizumab is a phase 1 stage product being developed by Erasca for Advanced or Metastatic Solid Tumors. The current trial status is active. This product is registered under clinical trial identifier NCT04670679. Target conditions include Advanced or Metastatic Solid Tumors.
Hype Score Breakdown
Clinical
10
Activity
5
Company
7
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04670679 | Phase 1 | Active |
Competing Products
20 competing products in Advanced or Metastatic Solid Tumors